European Journal of Cancer
Volume 37, Issue 14 , Pages 1775-1780 , September 2001

Early withdrawal from cervical cancer screening: the question of cost-effectiveness

  • Z Philips

      Affiliations

    • Health Economics Unit, Trent Institute for Health Services Research, University of Nottingham, Nottingham, UK
    • ,
  • D.K Whynes

      Affiliations

    • School of Economics, University of Nottingham, Nottingham NG7 2RD, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-115-951-5463; fax: +44-115-951-4159

Received 24 April 2001 ,Accepted 25 May 2001.

References 

  1. Miller AB. The status of screening for cervical cancer. Cancer Strategy. 1999;1:5–7
  2. Sung H-Y, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaiou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88:2283–2289
  3. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of the cervix in England (evaluation based on routinely collected statistics). BMJ. 1999;318:904–908
  4. Fahs MC, Plichta SB, Mandelblatt JS. Cost-effective policies for cervical screening (an international review). Pharmacoeconomics. 1996;9:211–230
  5. Koopmanschap MA, Luube KN, van Oortmarssen GJ, van Agt HM, van Ballegooijen M, Habbema JD. Economic aspects of cervical cancer screening. Soc. Sci. Med. 1990;30:1081–1087
  6. Gyrd-Hansen D, Holund B, Andersen P. A cost-effectiveness analysis of cervical cancer screening (health policy implications). Health Policy. 1995;34:35–51
  7. Gyrd-Hansen D. Is it cost-effective to introduce screening programmes for colorectal cancer? Illustrating the principles of optimal resource allocation. Health Policy. 1997;41:189–199
  8. Waugh N, Smith I, Robertson A, Reid G, Halkerston R, Grants A. Costs and benefits of cervical screening III. Costs/benefit analysis of a call of previously unscreened women. Cytopathol. 1996;7:249–255
  9. Waugh N, Robertson A. Costs and benefits of cervical screening II. Is it worthwhile reducing the screening interval from 5 to 3 years?. Cytopathol. 1996;7:241–248
  10. Grant CM. Cervical screening interval (costing the options in one health authority). J. Public Health Med. 1999;21:140–144
  11. van Wijngaarden WJ, Duncan ID. Rationale for stopping screening in women over 50. BMJ. 1993;306:967–971
  12. McKenzie CA, Duncan ID. The value of cervical screening in women over 50 years of age (time for a multicentre audit). Scottish Med. J. 1998;43:19–20
  13. Schiffman MH, Sherman ME. HPV testing to improve cervical cancer screening. In:  Srivastava S,  Lippman SM,  Hong WK,  Mulshine JI editor. Early Detection of Cancer (Molecular Markers). New York: Futura Publishing; 1994;p. 265–277
  14. Cuzick J, Sasieni P, Davies P, et al.  A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol. Assess. 1999;3:1–204
  15. Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes (mathematical modelling study). BMJ. 1999;318:356–361
  16. Sherlaw-Johnson C, Gallivan S, Jenkins D, Jones M. Cytological screening and management of abnormalities in prevention of cervical cancer (an overview with stochastic modelling). J. Clin. Pathol. 1994;47:430–435
  17. Wolstenholme J, Whynes D. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur. J. Cancer. 1998;34:1889–1893
  18. Waugh N, Smith I, Robertson A, Reed G, Halkerston R, Grant A. Costs and benefits of cervical screening I. The costs of the cervical screening programme. Cytopathol. 1996;7:231–240
  19. Cuzick J, Saseini P. Estimates of the cost impact of introducing human papillomavirus testing into a cervical screening programme. In:  Franco E,  Monsonego J, et al. editor. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell; 1997;
  20. Cuzick J, Szarewski A, Terry G, et al.  Human papillomavirus testing in primary cervical screening. Lancet. 1995;345:1533–1536
  21. Office of National Statistics . Mortality statistics (general (Series DH1 No 30)). London: The Stationary Office; 1999;
  22. Coleman MP, Babb P, Damiecki P, et al.  Cancer Survival Trends in England and Wales, 1971–1995 (Studies in Medical and Population Subjects 61). London: The Stationary Office; 1999;
  23. Office of National Statistics . Cancer Statistics (Registrations (Series MB1 No 27)). London: The Stationery Office; 2000;
  24. Robinson R. Limits to rationality (economics, economists and priority setting). Health Policy. 1999;49:13–26

PII: S0959-8049(01)00199-X

European Journal of Cancer
Volume 37, Issue 14 , Pages 1775-1780 , September 2001

Article Tools